Wellcome Trust Centre for Molecular Parasitology, Institute of Infection, Immunity and Inflammation, College of Medical, Veterinary and Life Sciences, University of Glasgow, 120 University Place, Glasgow, Scotland, United Kingdom.
Antimicrob Agents Chemother. 2012 Mar;56(3):1190-201. doi: 10.1128/AAC.05528-11. Epub 2011 Dec 5.
Cysteine peptidases have been implicated in the development and pathogenesis of Eimeria. We have identified a single-copy cathepsin B-like cysteine peptidase gene in the genome database of Eimeria tenella (EtCatB). Molecular modeling of the predicted protein suggested that it differs significantly from host enzymes and could be a good drug target. EtCatB was expressed and secreted as a soluble, active, glycosylated mature enzyme from Pichia pastoris. Biochemical characterization of the recombinant enzyme confirmed that it is cathepsin B-like. Screening of a focused library against the enzyme identified three inhibitors (a nitrile, a thiosemicarbazone, and an oxazolone) that can be used as leads for novel drug discovery against Eimeria. The oxazolone scaffold is a novel cysteine peptidase inhibitor; it may thus find widespread use.
半胱氨酸蛋白酶在艾美耳球虫的发生和发病机制中起作用。我们在柔嫩艾美耳球虫基因组数据库中鉴定到一个单拷贝的组织蛋白酶 B 样半胱氨酸蛋白酶基因(EtCatB)。对预测蛋白的分子建模表明,它与宿主酶有很大不同,可能是一个很好的药物靶点。EtCatB 从毕赤酵母中以可溶性、活性、糖基化的成熟酶形式表达和分泌。重组酶的生化特性鉴定证实其为组织蛋白酶 B 样酶。针对该酶的靶向文库筛选鉴定到三种抑制剂(一种腈、一种硫代缩氨基脲和一种恶唑酮),可作为针对艾美耳球虫的新型药物发现的先导化合物。恶唑酮骨架是一种新型的半胱氨酸蛋白酶抑制剂;因此,它可能有广泛的用途。